NeuroPace (NPCE) Net Cash Flow Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 269.22% |
| 10 | NeuroPace | 470.13 Mn | 418.43 Mn | 18.91 Mn | -66.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -66.37% |
| Mar 31, 2026 | -282.05% |
| Dec 31, 2025 | 5.42% |
| Sep 30, 2025 | -301.60% |
| Jun 30, 2025 | -31.34% |
| Mar 31, 2025 | 46.74% |
| Dec 31, 2024 | 36.67% |
| Sep 30, 2024 | 36.57% |
| Jun 30, 2024 | -26.21% |
| Mar 31, 2024 | 26.19% |
| Dec 31, 2023 | 35.74% |
| Sep 30, 2023 | -61.70% |
| Jun 30, 2023 | 18.73% |
| Mar 31, 2023 | -72.53% |